Deborah Waterhouse Named GSK’s ViiV Healthcare CEO
As ViiV Healthcare CEO, Dr. Dominique Limet stepped down after serving seven years, and the pharma giant tapped Deborah Waterhouse, the current SVP of Primary Care, as CEO, effective as of this month. Waterhouse joined GSK in 1996, and has held several roles at the company, including the head of the U.S. vaccines business. With an impressive track record in both primary and specialty care, she led the HIV business in the UK. Waterhouse also served in several roles in Central and Eastern Europe, Asia, Australia, and New Zealand, and now leads Viiv, which focuses on HIV treatments.
David Redfern, Chairman of ViiV Healthcare, said in a statement, “I look forward to working with Deborah, a leader who is known for listening to the customer and to her teams, and someone I know is very passionate about innovation in HIV therapy and access.”
Roche’s Genentech Taps Morgan Freeman for Cancer PSA
Genentech, in partnership with Stand Up To Cancer, on-boarded Academy Award-winning actor, Morgan Freeman, to appear in a new PSA campaign, Be the Breakthrough, to be executed across TV, print, radio, digital, and social media. This follows on the heels of the success of the documentary, The C Word, which Freeman directed and narrated to change public perception about cancer and the ways in which it can be fought—and received critical acclaim for his work.
“I am honored to join Stand Up To Cancer and Genentech in this extremely important PSA campaign,” the Academy Award-winning actor said in a statement to Broadwayworld.com. “Even the smallest steps against cancer are breakthroughs and can lead to something extraordinary.”
After a sales fraud scandal, current CEO David Hallal and CFO Vikas Sinha are stepping down. Honeywell’s 11-year CFO, David Anderson will take over as CFO, and former AstraZeneca Plc chief David Brennan will take over as interim CEO. They will lead Alexion when it is in prime position for a label expansion for Soliris that should bring in $200 million in sales by 2020.
Nadia Whittley was appointed CEO of Arquer, a UK-based oncology diagnostics firm. She leaves her role as Partner and Managing Director of Tefen Management Consulting to lead strategic direction of the life science business unit. Previously, she held leadership positions at Alium Medical, Allergan, and Boston Scientific.
David Pernock joined Eagle as President and Chief Commercial Officer. Pernock has been a member of Eagle’s Board of Directors since April 2015. He has vast experience in pharma and biotech leadership and will be responsible for all commercial strategy and execution for Eagle’s product portfolio.
Donald Hanson will take on the role of Vice President of Client Services at Intouch Solutions, a leading pharma marketing agency. Since joining Intouch in 2013 as Group Account Director serving in the agency’s Chicago office, he brought extensive knowledge and an ability to think outside the box. Hanson has excelled and gained the skills necessary to lead teams to provide the best possible client experiences. He brings strategic enterprise solutions to the table and has grown his business and team each year he has been with Intouch.
David Schilansky will join the Board of Directors at Lysogene, a pharma company that focuses on gene therapy for rare nervous system diseases, as a non-executive and independent member. Schilansky brings 20 years of experience and is currently Deputy CEO and Chief Operating Officer at DBV Technologies.
Dr. Colin Goddard has been appointed non-executive Chairman, having served the board of the company as a non-executive Director since 2015. Previously, Dr. Goddard was CEO of OSI Pharmaceuticals, a company he joined as a research scientist in 1989.
Founder Ryan Abbate will be inducted into the Medical Advertising Hall of Fame. Abbate built the largest healthcare marketing agency on the West Coast, representing giants including Pfizer and Medtronic. After 30 years, Abbate became an innovator in digital marketing for healthcare products and the pioneer of television commercials for pharmaceutical drugs, setting the standard for the industry. PACIFIC will also welcome Senior Vice President, Director of Client Services, Judy Doo. She brings 20 years of experience in global healthcare communications having previously served as director at ALASTIN Skincare in Carlsbad, California.
Prothena Corp., a biotechnology company specializing in commercialization of protein immunotherapies, has appointed Carol D. Karp Chief Regulatory Officer to lead their Quality, Regulatory, and Safety Organizations. Prior to joining Prothena, Karp was a successful independent regulatory consultant. She also previously held several regulatory leadership positions at companies including Esperion Therapeutics, Janssen Alzheimer Immunotherapy, CV Therapeutics, PowderJect, and VIVUS.
Dipankar Bhattacharjee, the current President and CEO of Teva Generics Europe, will begin a new role as President and CEO of Teva’s Global Generic Medicines Group, succeeding Sigurdur (Siggi) Olafsson as he steps down from the position. Bhattacharjee comes in at a turbulent time, just a few months after Teva acquired Allergan’s generics unit in a $40.5 billion deal. Prior to his seven years at Teva, he spent 15 years serving in leadership positions at Bausch + Lomb.
Matthew Kapusta will take over as CEO for uniQure, a Dutch gene therapy company in its third year. Kapusta has served as CFO since 2015, as the company launched the world’s most expensive drug, Glybera. Kapusta is expected to bring uniQure’s new hemophilia B program to commercial success.
William Humphries has been appointed EVP, Dermatology. He will use his 30 years of commercial and operational experience gained as CEO of Merz North America and VP of Allergan’s U.S. skincare business, to revive Valeant’s dermatology unit.